Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Michelle Del Vecchio"'
Autor:
Gabriella Liszkay, Catriona McNeil, Michele Maio, Vanna Chiarion-Sileni, Luc Thomas, Andrzej Mackiewicz, Michelle Del Vecchio, Ana Arance, Laurent Mortier, Lars Bastholt, Brigitte Dreno, Marta Nyakas, Michael Smylie, Christoph Hoeller, Virginia Ferraresi, Florent Grange, Joanna Pikiel, Fareeda Hosein, Burcin Simsek
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background We have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analys
Externí odkaz:
https://doaj.org/article/4bc8bf865c8940309a0da0ece09a1891
Autor:
Vanna Chiarion-Sileni, Céleste Lebbé, Catriona M. McNeil, Joanna Pikiel, Jean-Jacques Grob, Luc Thomas, Lars Bastholt, Andrzej Mackiewicz, Michele Maio, Omid Hamid, Virginia Ferraresi, Marta Nyakas, Caroline Robert, Michelle Del Vecchio, Burcin Simsek, Michael Smylie, Laurent Mortier, Dirk Schadendorf, Carmen Loquai, Inge Marie Svane, Ana Arance, Gabriella Liszkay, Fareeda Hosein, Piotr Rutkowski, Paolo A. Ascierto, Florent Grange, Christoph Hoeller, Brigitte Dréno, Ralf Gutzmer, Claus Garbe
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 2020, 8 (1), pp.e000391. ⟨10.1136/jitc-2019-000391⟩
Ascierto, P A, Del Vecchio, M, Mackiewicz, A, Robert, C, Chiarion-Sileni, V, Arance, A, Lebbé, C, Svane, I M, Mcneil, C, Rutkowski, P, Loquai, C, Mortier, L, Hamid, O, Bastholt, L, Dreno, B, Schadendorf, D, Garbe, C, Nyakas, M, Grob, J J, Thomas, L, Liszkay, G, Smylie, M, Hoeller, C, Ferraresi, V, Grange, F, Gutzmer, R, Pikiel, J, Hosein, F, Simsek, B & Maio, M 2020, ' Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma ', Journal for ImmunoTherapy of Cancer, vol. 8, no. 1, e000391 . https://doi.org/10.1136/jitc-2019-000391
Ascierto, P A, Del Vecchio, M, Mackiewicz, A, Robert, C, Chiarion-Sileni, V, Arance, A, Lebbé, C, Svane, I M, Mcneil, C, Rutkowski, P, Loquai, C, Mortier, L, Hamid, O, Bastholt, L, Dreno, B, Schadendorf, D, Garbe, C, Nyakas, M, Grob, J J, Thomas, L, Liszkay, G, Smylie, M, Hoeller, C, Ferraresi, V, Grange, F, Gutzmer, R, Pikiel, J, Hosein, F, Simsek, B & Maio, M 2020, ' Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma ', Journal for immunotherapy of cancer, vol. 8, no. 1, e000391 . https://doi.org/10.1136/jitc-2019-000391
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for Immunotherapy of Cancer, 2020, 8 (1), pp.e000391. ⟨10.1136/jitc-2019-000391⟩
Ascierto, P A, Del Vecchio, M, Mackiewicz, A, Robert, C, Chiarion-Sileni, V, Arance, A, Lebbé, C, Svane, I M, Mcneil, C, Rutkowski, P, Loquai, C, Mortier, L, Hamid, O, Bastholt, L, Dreno, B, Schadendorf, D, Garbe, C, Nyakas, M, Grob, J J, Thomas, L, Liszkay, G, Smylie, M, Hoeller, C, Ferraresi, V, Grange, F, Gutzmer, R, Pikiel, J, Hosein, F, Simsek, B & Maio, M 2020, ' Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma ', Journal for ImmunoTherapy of Cancer, vol. 8, no. 1, e000391 . https://doi.org/10.1136/jitc-2019-000391
Ascierto, P A, Del Vecchio, M, Mackiewicz, A, Robert, C, Chiarion-Sileni, V, Arance, A, Lebbé, C, Svane, I M, Mcneil, C, Rutkowski, P, Loquai, C, Mortier, L, Hamid, O, Bastholt, L, Dreno, B, Schadendorf, D, Garbe, C, Nyakas, M, Grob, J J, Thomas, L, Liszkay, G, Smylie, M, Hoeller, C, Ferraresi, V, Grange, F, Gutzmer, R, Pikiel, J, Hosein, F, Simsek, B & Maio, M 2020, ' Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma ', Journal for immunotherapy of cancer, vol. 8, no. 1, e000391 . https://doi.org/10.1136/jitc-2019-000391
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundWe have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::510133352a63b0beb0ad853bb98c25db
https://www.ncbi.nlm.nih.gov/pubmed/32503946
https://www.ncbi.nlm.nih.gov/pubmed/32503946